stockrowKymera Therapeutics, Inc.
KYMR Healthcare Biotechnology
Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024.
- Revenue
- +466.4%
- EPS
- −40.3%
- Free cash flow
- −186.6%
- Total debt
- −66.6%
Quarter to September 2026, against a year earlier
Follow KYMR
Alert me
Kymera Therapeutics, Inc. (KYMR) Net margin
Kymera Therapeutics, Inc.'s net margin over the twelve months to 30 September 2026 was 0.00%, up 794.0 percentage points from fiscal 2025 (−794.0%). Over the past ten years it has ranged from −1,405.8% (fiscal 2019) to 0.00% (fiscal 2018); the current reading is higher than 25% of that period. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Net margin, annual
Embed this chart
Annual newest first
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | −794.0% | (318.47) |
| FY2024 | −475.6% | (288.58) |
| FY2023 | −187.0% | 143.61 |
| FY2022 | −330.6% | (193.00) |
| FY2021 | −137.6% | 22.95 |
| FY2020 | −160.6% | 1,245.24 |
| FY2019 | −1,405.8% | (1,405.79) |
| FY2018 | 0.00% | — |
Quarterly newest first
| Period | Net margin | Change (points) |
|---|---|---|
| Sep 2026 | 0.00% | 94.17 |
| Jun 2026 | −94.2% | 107.30 |
| Mar 2026 | −201.5% | 2,828.17 |
| Dec 2025 | −3,029.6% | (56.59) |
| 24 more quarters | Free account |
Against its own ten years
Net margin against peers
| Company | Net margin |
|---|---|
| TGTX TG Therapeutics, Inc. compare | 55.2% |
| TECH Bio-Techne Corp compare | 15.0% |
| CAI Caris Life Sciences,�Inc. compare | 9.16% |
| PCVX Vaxcyte, Inc. compare | 0.00% |
| SMMT Summit Therapeutics PLC compare | 0.00% |
| KYMR Kymera Therapeutics, Inc. | 0.00% |
| BMRN BioMarin Pharmaceutical Inc. compare | −0.52% |
| TWST Twist Bioscience Corporation compare | −31.7% |
| IBRX ImmunityBio, Inc. compare | −598.6% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 1.06% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on KYMR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement